The average gap between NHI prices and the market prices of listed medicines in Japan stood at a preliminary 5.2%…
HOME > ARCHIVE
ARCHIVE
- Takeda Completes Computerization in Synthetic Study Dept.
September 13, 2010
- MSD to Enter PIII for Betrixaban in 2011
September 13, 2010
- RaQualia Licenses Acid Pump Antagonists to CJ Cheil Jedang
September 13, 2010
- Genetic Variability Does Not Affect Responses to Ticagrelor: PLATO Study Subanalysis
September 13, 2010
- Novartis Makes Alcon Consolidated Subsidiary
September 13, 2010
- Evidence on Diovan Accumulated in Japanese Patients
September 13, 2010
- Daiichi Sankyo Revises 1st Half FY2010 Business Forecasts Upward
September 13, 2010
- ACOS Focuses on Therapeutic Cancer Vaccines
September 13, 2010
- Fujifilm to Enter into Capital Partnership with J-TEC
September 13, 2010
- Sutent Does Not Extend OS in NSCLC in PIII: Pfizer
September 13, 2010
- New PFSB Director General to Place Top Priority on Prevention of Drug-Induced Health Damage
September 13, 2010
- Lilly Applies for Gemzar for Ovarian Cancer Based on Data from Public Domain
September 13, 2010
- Eisai Begins PI Study for BAN2401 in the US
September 13, 2010
- Korosho Demands ¥28,795.4 Bil. General Account Budget for FY2011
September 13, 2010
- Humira Applied for JIA in Japan: Abbott, Eisai
September 13, 2010
- No Significant Differences in ADRs between Avandia, Actos: HealthCore
September 13, 2010
- Korosho Demands Budgets to Develop Buried Seeds of Drugs
September 13, 2010
- FDA Extends Review of Eribulin NDA: Eisai
September 13, 2010
- Expand Range of Indications for Palivizumab: Dr Watabe
September 13, 2010
- Working Groups Created to Assess 8 Vaccines
September 13, 2010
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…